Irvine-based Allergan Inc. said Monday it’s acquired nearly all shares of Inamed Corp. of Santa Barbara.
Allergan has bought 95% of Inamed shares and expects to close the acquisition shortly.
The drug maker will “immediately start implementing our integration plan,” Allergan Chief Executive David Pyott said.
The Federal Trade Commission approved Allergan’s buy of Inamed earlier this month.
To get regulatory approval, Allergan agreed to sell Inamed’s rights to Reloxin, a potential competitor to Allergan’s flagship Botox drug.
Ipsen Ltd., a European drug maker, is taking back rights to Reloxin and plans to sell them to Medicis Pharmaceutical Corp. of Scottsdale, which lost the bidding war for Inamed to Allergan.
